FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904394271> ?p ?o ?g. }

• W2904394271 endingPage "2724" @default.
• W2904394271 startingPage "2717" @default.
• W2904394271 abstract "Abstract Purpose: To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer. Patients and Methods: ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II study of talazoparib (1 mg/day) in germline BRCA mutation carriers with a response to prior platinum with no progression on or within 8 weeks of the last platinum dose (cohort 1) or ≥3 platinum-free cytotoxic regimens (cohort 2) for advanced breast cancer. Primary endpoint was confirmed objective response rate (ORR) by independent radiological assessment. Results: We enrolled 84 patients (cohort 1, n = 49; cohort 2, n = 35) from May 2014 to February 2016. Median age was 50 (range, 31–75) years. Triple-negative breast cancer (TNBC) incidence was 59% (cohort 1) and 17% (cohort 2). Median number of prior cytotoxic regimens for advanced breast cancer was two and four, respectively. Confirmed ORR was 21% [95% confidence interval (CI), 10–35; cohort 1] and 37% [95% CI, 22–55; cohort 2]. Median duration of response was 5.8 and 3.8 months, respectively. Confirmed ORR was 23% (BRCA1), 33% (BRCA2), 26% (TNBC), and 29% (hormone receptor–positive). The most common all-grade adverse events (AE) included anemia (52%), fatigue (45%), and nausea (42%). Talazoparib-related AEs led to drug discontinuation in 3 (4%) patients. In an exploratory analysis, longer platinum-free interval was associated with higher response rate in cohort 1 (0% ORR with interval &lt;8 weeks; 47% ORR with interval &gt;6 months). Conclusions: Talazoparib exhibited promising antitumor activity in patients with advanced breast cancer and germline BRCA mutation." @default.
• W2904394271 created "2018-12-22" @default.
• W2904394271 creator A5001731251 @default.
• W2904394271 creator A5013148496 @default.
• W2904394271 creator A5017728105 @default.
• W2904394271 creator A5018270333 @default.
• W2904394271 creator A5045514288 @default.
• W2904394271 creator A5048706345 @default.
• W2904394271 creator A5052487618 @default.
• W2904394271 creator A5060044961 @default.
• W2904394271 creator A5065272343 @default.
• W2904394271 creator A5068059897 @default.
• W2904394271 creator A5070265480 @default.
• W2904394271 creator A5083605021 @default.
• W2904394271 creator A5089364285 @default.
• W2904394271 creator A5090188675 @default.
• W2904394271 date "2019-05-01" @default.
• W2904394271 modified "2023-10-16" @default.
• W2904394271 title "A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO)" @default.
• W2904394271 cites W1984629445 @default.
• W2904394271 cites W1989006164 @default.
• W2904394271 cites W2002962154 @default.
• W2904394271 cites W2065849886 @default.
• W2904394271 cites W2098737737 @default.
• W2904394271 cites W2111437716 @default.
• W2904394271 cites W2115773111 @default.
• W2904394271 cites W2199466904 @default.
• W2904394271 cites W2218100789 @default.
• W2904394271 cites W2308659819 @default.
• W2904394271 cites W2539944286 @default.
• W2904394271 cites W2557717244 @default.
• W2904394271 cites W2592941899 @default.
• W2904394271 cites W2597062310 @default.
• W2904394271 cites W2621271973 @default.
• W2904394271 cites W2741214285 @default.
• W2904394271 cites W2886477543 @default.
• W2904394271 doi "https://doi.org/10.1158/1078-0432.ccr-18-1891" @default.
• W2904394271 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30563931" @default.
• W2904394271 hasPublicationYear "2019" @default.
• W2904394271 type Work @default.
• W2904394271 sameAs 2904394271 @default.
• W2904394271 citedByCount "95" @default.
• W2904394271 countsByYear W29043942712019 @default.
• W2904394271 countsByYear W29043942712020 @default.
• W2904394271 countsByYear W29043942712021 @default.
• W2904394271 countsByYear W29043942712022 @default.
• W2904394271 countsByYear W29043942712023 @default.
• W2904394271 crossrefType "journal-article" @default.
• W2904394271 hasAuthorship W2904394271A5001731251 @default.
• W2904394271 hasAuthorship W2904394271A5013148496 @default.
• W2904394271 hasAuthorship W2904394271A5017728105 @default.
• W2904394271 hasAuthorship W2904394271A5018270333 @default.
• W2904394271 hasAuthorship W2904394271A5045514288 @default.
• W2904394271 hasAuthorship W2904394271A5048706345 @default.
• W2904394271 hasAuthorship W2904394271A5052487618 @default.
• W2904394271 hasAuthorship W2904394271A5060044961 @default.
• W2904394271 hasAuthorship W2904394271A5065272343 @default.
• W2904394271 hasAuthorship W2904394271A5068059897 @default.
• W2904394271 hasAuthorship W2904394271A5070265480 @default.
• W2904394271 hasAuthorship W2904394271A5083605021 @default.
• W2904394271 hasAuthorship W2904394271A5089364285 @default.
• W2904394271 hasAuthorship W2904394271A5090188675 @default.
• W2904394271 hasBestOaLocation W29043942712 @default.
• W2904394271 hasConcept C121608353 @default.
• W2904394271 hasConcept C126322002 @default.
• W2904394271 hasConcept C143998085 @default.
• W2904394271 hasConcept C2775930923 @default.
• W2904394271 hasConcept C2780194787 @default.
• W2904394271 hasConcept C530470458 @default.
• W2904394271 hasConcept C71924100 @default.
• W2904394271 hasConcept C72563966 @default.
• W2904394271 hasConceptScore W2904394271C121608353 @default.
• W2904394271 hasConceptScore W2904394271C126322002 @default.
• W2904394271 hasConceptScore W2904394271C143998085 @default.
• W2904394271 hasConceptScore W2904394271C2775930923 @default.
• W2904394271 hasConceptScore W2904394271C2780194787 @default.
• W2904394271 hasConceptScore W2904394271C530470458 @default.
• W2904394271 hasConceptScore W2904394271C71924100 @default.
• W2904394271 hasConceptScore W2904394271C72563966 @default.
• W2904394271 hasFunder F4320307765 @default.
• W2904394271 hasIssue "9" @default.
• W2904394271 hasLocation W29043942711 @default.
• W2904394271 hasLocation W29043942712 @default.
• W2904394271 hasLocation W29043942713 @default.
• W2904394271 hasOpenAccess W2904394271 @default.
• W2904394271 hasPrimaryLocation W29043942711 @default.
• W2904394271 hasRelatedWork W144521535 @default.
• W2904394271 hasRelatedWork W2012143939 @default.
• W2904394271 hasRelatedWork W2037999876 @default.
• W2904394271 hasRelatedWork W2070780645 @default.
• W2904394271 hasRelatedWork W2245189862 @default.
• W2904394271 hasRelatedWork W2411890706 @default.
• W2904394271 hasRelatedWork W2979892935 @default.
• W2904394271 hasRelatedWork W3112166790 @default.
• W2904394271 hasRelatedWork W3181412252 @default.
• W2904394271 hasRelatedWork W377899687 @default.
• W2904394271 hasVolume "25" @default.
• W2904394271 isParatext "false" @default.

• next